The move could lead to a reduction of 700 Pharmaceutical Jobs, according to a development reported by La Tribune.
The reshuffle is part of a strategic plan called Transforming which was launched by the French drugmaker in 2009, the newspaper added, citing a union source.
In another development, it has emerged that Sanofi-Aventis’ planned $20.1 billion purchase of Cambridge biotech giant Genzyme could lead to local cuts in administrative positions, but might also create new R&D and manufacturing jobs. According to Bostonherald.com, Genzyme chief Henri Termeer said that some of his company’s current jobs “related to the administration of a public company (are) probably not necessary” once Sanofi and Genzyme merge later this year.
Late last month, it also merged that Genzyme expects a new round of layoffs to result in charges of $16 million to $23 million. As far as the impact on biotech jobs is concerned, as per a Securities and Exchange Commission filing, the company is cutting 170 positions in the second phase of the layoff plan. The cuts include 60 unfilled positions and 40 jobs in San Diego, where it is closing a facility, reported the AP. The report added that Genzyme is offering severance packages to laid-off workers in the US and similar packages to employees outside the U.S. in accordance with local laws.
No comments:
Post a Comment